Abstract
Retinal neovascularization is a feature shared by many disease processes including diabetic retinopathy, retinopathy of prematurity, branch retinal vein occlusion and central retinal vein occlusion, which are collectively referred to as ischemic retinopathy (Campochiaro, 2000). Retinal neovascularization is the most common cause of blindness in young diabetic patients. Investigations of the pathogenic mechanisms and therapeutic interventions for retinal neovascularization require reproducible and clinically related animal models. Currently, all diabetic models exhibit only early retinal vasculopathy after 1 or 2 years of the disease (Kondo and Kahn, 2004). The lack of retinal neovascularization in diabetic models is probably due to the natural short life span of rodents (2–3 years). In humans, DR is detected only after at least 3 years of diabetes (Dorchy et al., 2002). As angiogenesis is tightly controlled by the relative balance of stimulators and inhibitors, a shift in their balance, such as increased expression of vascular endothelial growth factor (VEGF) or decreased production of pigment epithelium-derived factor, would initiate angiogenesis (Okamoto et al., 1997; Ruberte et al., 2004; Renno et al., 2002). It is clear from literature that ischemia-induced upregulation of VEGF is a potent mediator of retinal neovascularization (Campochiaro, 2000; Miller, 1997). Animal models of retinal neovascularization have been established by oxygen-induced retinal ischemia, photodynamically-induced retinal branch vein occlusion and intravitreal implantation of VEGF sustained-release pellets (Campochiaro, 2000; Saito et al., 1997; Ozaki et al., 1997; Tolentino et al., 2002). However, retinal neovascularization in these animal models is either transient or occurs with a delayed onset.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bainbridge JW, Mistry AR, Thrasher AJ, Ali RR (2003). Gene therapy for ocular angiogenesis. Clin Sci 104:561–75.
Barber AJ (2003). A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 27:283–90.
Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW (1998). Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 102:783–91.
Campochiaro PA (2000). Retinal and choroidal neovascularization. J Cell Physiol 184:301–10.
Campochiaro PA (2002). Gene therapy for retinal and choroidal diseases. Expert Opin Biol Ther 2:537–44.
Dorchy H, Claes C, Verougstraete C (2002). Risk factors of developing proliferative retinopathy in type 1 diabetic patients: role of BMI. Diabetes Care 25:798–9.
Igarashi T, Miyake K, Kato K et al (2003). Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model. Gene Ther 10:219–26.
Kondo T, Kahn CR (2004). Altered insulin signaling in retinal tissue in diabetic states. J Biol Chem 279:37997–8006.
Lai CM, Dunlop SA, May LA et al (2004). Generation of transgenic mice with mild and severe retinal neovascularisation. Br J Ophthalmol (in press).
Miller JW (1997). Vascular endothelial growth factor and ocular neovascularization. Am J Pathol 151:13–23.
Okamoto N, Tobe T, Hackett SF et al (1997). Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151:281–91.
Ozaki H, Hayashi H, Vinores SA, Moromizato Y, Campochiaro PA, Oshima K (1997). Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates. Exp Eye Res 64:505–17.
Rakoczy PE, Brankov M, Fonceca A, Zaknich T, Rae BC, Lai CM (2003). Enhanced recombinant adeno-associated virus-mediated vascular endothelial growth factor expression in the adult mouse retina: a potential model for diabetic retinopathy. Diabetes 52:857–63.
Renno RZ, Youssri AI, Michaud N, Gragoudas ES, Miller JW (2002). Expression of pigment epithelium-derived factor in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 43:1574–80.
Rota R, Riccioni T, Zaccarini M et al (2004). Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer. J Gene Med 6:992–1002.
Ruberte J, Ayuso E, Navarro M et al (2004). Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest 113:1149–57.
Saito Y, Park L, Skolik SA et al (1997). Experimental preretinal neovascularization by laser-induced venous thrombosis in rats. Curr Eye Res 16:26–33.
Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA (2002). Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133:373–85.
Wang F, Rendahl KG, Manning WC, Quiroz D, Coyne M, Miller SS (2003). AAV-mediated expression of vascular endothelial growth factor induces choroidal neovascularization in rat. Invest Ophthalmol Vis Sci 44:781–90.
Zaknich T, Shen WY, Barry CJ, Brankov M, Rakoczy PE (2002). Modification of clinical cameras for documentation of small laboratory animals. Ophthalmic Photography 24:66–9.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this paper
Cite this paper
Shen, WY. et al. (2006). Pathological Heterogeneity of Vasoproliferative Retinopathy in Transgenic Mice Overexpressing Vascular Endothelial Growth Factor in Photoreceptors. In: Hollyfield, J.G., Anderson, R.E., LaVail, M.M. (eds) Retinal Degenerative Diseases. Advances in Experimental Medicine and Biology, vol 572. Springer, Boston, MA. https://doi.org/10.1007/0-387-32442-9_28
Download citation
DOI: https://doi.org/10.1007/0-387-32442-9_28
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-28464-4
Online ISBN: 978-0-387-32442-5
eBook Packages: MedicineMedicine (R0)